Rockefeller Capital Management
BBIO icon

Rockefeller Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Rockefeller Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.98M Buy
53,621
+15,192
+40% +$1.1M 0.01% 1012
2025
Q4 		$2.94M Buy
38,429
+25,169
+190% +$1.65M 0.01% 1084
2025
Q3 		$689K Sell
13,260
-25,506
-66% -$1.24M ﹤0.01% 1615
2025
Q2 		$1.67M Buy
38,766
+21,531
+125% +$783K ﹤0.01% 1170
2025
Q1 		$596K Sell
17,235
-24,054
-58% -$811K ﹤0.01% 1431
2024
Q4 		$1.13M Buy
41,289
+30
+0.1% +$775 ﹤0.01% 1202
2024
Q3 		$1.05M Buy
41,259
+4,317
+12% +$113K ﹤0.01% 1211
2024
Q2 		$936K Sell
36,942
-4,070
-10% -$111K ﹤0.01% 1228
2024
Q1 		$1.27M Sell
41,012
-480
-1% -$16.3K ﹤0.01% 1176
2023
Q4 		$1.68M Sell
41,492
-700
-2% -$21K 0.01% 977
2023
Q3 		$1.11M Sell
42,192
-16,278
-28% -$462K ﹤0.01% 1046
2023
Q2 		$1.01M Buy
58,470
+9,268
+19% +$139K ﹤0.01% 1079
2023
Q1 		$815K Buy
49,202
+3,885
+9% +$45.3K ﹤0.01% 1148
2022
Q4 		$345K Sell
45,317
-5,046
-10% -$48.3K ﹤0.01% 1418
2022
Q3 		$500K Sell
50,363
-16,476
-25% -$171K ﹤0.01% 1268
2022
Q2 		$606K Sell
66,839
-23,449
-26% -$196K ﹤0.01% 1185
2022
Q1 		$915K Sell
90,288
-1,018,945
-92% -$10.5M ﹤0.01% 1085
2021
Q4 		$18.5M Buy
1,109,233
+272,319
+33% +$11.5M 0.09% 232
2021
Q3 		$39.2M Buy
836,914
+4,830
+0.6% +$259K 0.21% 119
2021
Q2 		$50.7M Buy
832,084
+12,452
+2% +$711K 0.29% 79
2021
Q1 		$50.5M Buy
819,632
+42,601
+5% +$2.79M 0.34% 66
2020
Q4 		$55.3M Buy
+777,031
New +$37.5M 0.42% 51

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rockefeller Capital Management's BBIO Position: Q1 2026 in Review

Rockefeller Capital Management increased its BridgeBio Pharma (BBIO) stake by 40% in Q1 2026, buying an estimated $1.1M and bringing the position to 53,621 shares worth $3.98M. The position accounts for 0.01% of the portfolio, ranked #1012.

Rockefeller Capital Management first reported a position in BBIO in Q4 2020 and has held it in 22 quarters since. The position peaked at $55.3M in Q4 2020. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Rockefeller Capital Management held 53,621 shares of BridgeBio Pharma worth $3.98M as of Q1 2026.
  • Rockefeller Capital Management bought 15,192 BridgeBio Pharma shares in Q1 2026, an estimated $1.1M.
  • BridgeBio Pharma made up 0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #1012 holding.
  • Rockefeller Capital Management first reported a position in BridgeBio Pharma in Q4 2020 and has held it in 22 quarters since.
  • Rockefeller Capital Management's BridgeBio Pharma position peaked at $55.3M in Q4 2020.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.